Given the trial evidence of effectiveness in COVID-19 and supporting genetic evidence in sepsis, we aimed to investigate whether IL-6 downregulation might also lead to improved outcomes in severe malaria and whether this might represent a common target for severe infection. The gene discussed is IL6; the disease is malaria.